PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35274449-1	2022	BACKGROUND: Because of the approved immunomodulatory activities of fingolimod, the current study aimed at studying the curative potential of fingolimod against experimentally induced ulcerative colitis (UC) via modulating pro/anti-inflammatory cytokines release and AKT/mTOR signalling.	Fingolimod Hydrochloride	141-151	mechanistic target of rapamycin kinase	Rattus norvegicus	270-274	
30550889-14	2019	SIGNIFICANCE: Our results indicated that FTY720 inhibited PSC activation by promoting cell apoptosis and inhibiting PSC autophagy by suppressing AMPK and activating the mTOR pathway.	Fingolimod Hydrochloride	41-47	mechanistic target of rapamycin kinase	Rattus norvegicus	169-173	
35274449-0	2022	Fingolimod ameliorates acetic acid-induced ulcerative colitis: An insight into its modulatory impact on pro/anti-inflammatory cytokines and AKT/mTOR signalling.	Fingolimod Hydrochloride	0-10	mechanistic target of rapamycin kinase	Rattus norvegicus	144-148	
35274449-10	2022	In addition, fingolimod decreased the expressions of AKT and mTOR compared to the UC group.	Fingolimod Hydrochloride	13-23	mechanistic target of rapamycin kinase	Rattus norvegicus	61-65	
35274449-11	2022	CONCLUSION: Fingolimod attenuated acetic acid-induced UC through its immunomodulatory effect by shifting the balance to favour anti-inflammatory cytokine production rather than pro-inflammatory cytokines and modulating the AKT/mTOR signalling.	Fingolimod Hydrochloride	12-22	mechanistic target of rapamycin kinase	Rattus norvegicus	227-231